Artificial Intelligence in Drug Development and Clinical Trials

The webinar will explain how disrupting technologies and novel concepts impact the way clinical trials are designed and executed. This new age of clinical trial advancements means that Sponsors and all trial stakeholders, including the sites and technology partners must evolve to meet the demands of this new paradigm. In this talk, Dr Kubassova will talk about the fundamentals of a digital strategy, which is needed to leverage novel technologies within clinical trials. She will also speak about data-driven approach to drug development and cover how integrating AI into drug development process affects cost, speed and success of pharmaceutical drug development. You can bring these fundamentals with you into development of drugs in a particular indication or conducting a real-world evidence study.
Chair:
Mathew Cherian, VP of Operations & Development, ReVive Biotechnology, United States
Co-moderator:
Nikolina Biskic, Regulatory Affairs Manager, Switzerland
Panellist:
Olga Kubassova, Founder and President of Image Analysis Group, UK